|
Logo placeholder
|
| Location |
Los Angeles, CA, USA |
| Type |
University |
| Website |
https://www.ucla.edu/ |
| Focus Areas |
[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Clinical Trials](/clinical-trials) |
| Departments |
Department of Neurology
Easton Center for Alzheimer's Disease Research
Brain Research Institute |
University of California Los Angeles (UCLA) is a world-renowned research university located in Los Angeles, California. The institution has established itself as a major center for neurodegenerative disease research, with particularly strong programs in Alzheimer's disease, Parkinson's disease, and related disorders. Through its Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, and Brain Research Institute, UCLA supports multidisciplinary investigation into the mechanisms, diagnosis, and treatment of neurodegenerative diseases.
UCLA's neurodegenerative disease research program represents one of the most comprehensive in the United States, spanning basic science, translational research, and clinical care. The institution's location in Los Angeles provides access to a diverse patient population, while its strong basic science departments enable cutting-edge investigation into disease mechanisms. UCLA researchers have made fundamental contributions to understanding Alzheimer's disease and Parkinson's disease pathogenesis, developing novel biomarkers, and advancing clinical trial design.
¶ History and Institutional Context
UCLA was founded in 1919 as the Southern Branch of the University of California and has grown to become one of the world's leading public research universities. The university's health sciences center, including the David Geffen School of Medicine, has been particularly influential in neuroscience research.
The Mary S. Easton Center for Alzheimer's Disease Research was established to coordinate Alzheimer's disease research across UCLA and has become a major contributor to national and international research efforts. Similarly, the Parkinson's disease program has grown to encompass comprehensive care, research, and education.
UCLA maintains one of the most active Alzheimer's disease research programs in the world. Key research themes include:
¶ Genetics and Molecular Pathogenesis
UCLA researchers investigate the genetic basis of Alzheimer's disease, including:
- APP and Presenilin Genes: Early-onset Alzheimer's disease genetics
- APOE Variants: Risk modification by APOE alleles
- TREM2 and Microglial Genes: Immune-related genetic risk factors
- Genome-Wide Studies: Identification of novel risk genes through GWAS
The identification of genetic risk factors has provided insights into disease mechanisms and potential therapeutic targets.
UCLA has been at the forefront of biomarker development:
- PET Imaging: Development of amyloid and tau PET ligands for in vivo visualization of pathology
- CSF Biomarkers: Analysis of cerebrospinal fluid for Aβ, tau, and neurodegeneration markers
- Blood Biomarkers: Development of plasma tests for early detection
- Digital Biomarkers: App-based cognitive assessments for remote monitoring
These biomarkers enable early diagnosis, disease staging, and monitoring of treatment response.
UCLA serves as a major clinical trial site for Alzheimer's disease therapeutics:
- Anti-Amyloid Therapies: Participation in trials of monoclonal antibodies targeting amyloid-beta
- Anti-Tau Therapies: Trials of treatments targeting tau pathology
- Symptomatic Treatments: Studies of cognitive enhancers and disease modification
- Prevention Trials: Trials in cognitively normal individuals at risk for Alzheimer's disease
The institution's clinical trial infrastructure enables rapid translation of basic science discoveries to clinical application.
¶ Parkinson's Disease and Movement Disorders
UCLA's movement disorder program addresses Parkinson's disease and related conditions:
Investigations into Parkinson's disease mechanisms include:
- Alpha-Synuclein Biology: Studies of aggregation and propagation
- Mitochondrial Dysfunction: Investigation of complex I impairment
- Neuroinflammation: Role of microglia in disease progression
- LRRK2 and Genetic Forms: Studies of genetic Parkinson's disease
Understanding these mechanisms identifies potential therapeutic targets.
UCLA has been a pioneer in deep brain stimulation (DBS) therapy:
- Surgical Targets: Optimization of stimulation targets (STN, GPi)
- Programming Techniques: Development of adaptive stimulation approaches
- Novel Indications: DBS for dementia and psychiatric conditions
- Mechanisms: Understanding how DBS modifies neural circuits
DBS represents one of the most effective treatments for advanced Parkinson's disease.
¶ Lewy Body Dementia
UCLA researchers investigate Lewy body dementia, the second most common neurodegenerative dementia:
- Clinical Features: Characterization of cognitive, motor, and behavioral symptoms
- Neuropathology: Understanding alpha-synuclein deposition patterns
- Biomarkers: Development of diagnostic and prognostic markers
- Treatment: Optimizing pharmacological and non-pharmacological management
The UCLA Brain Imaging Center provides state-of-the-art neuroimaging capabilities:
- Structural MRI: Volumetric analysis of brain atrophy
- Diffusion Tensor Imaging: White matter integrity assessment
- Functional MRI: Brain activation patterns during tasks
- Resting State: Functional connectivity analysis
- Amyloid PET: Florbetapir, florbetaben imaging
- Tau PET: Flortaucipir and newer tau ligands
- FDG PET: Metabolic pattern analysis
- Receptor Imaging: Dopaminergic and other receptor studies
These imaging modalities enable visualization of pathology and monitoring of disease progression.
UCLA researchers utilize stem cell models to study neurodegeneration:
- Induced Pluripotent Stem Cells: Patient-derived neurons for disease modeling
- Differentiation Protocols: Methods for generating specific neuronal subtypes
- Disease Modeling: Investigation of disease mechanisms in cell culture
- Drug Screening: High-throughput testing of therapeutic compounds
Stem cell technology provides human disease models that complement animal studies.
The intersection of immunology and neurodegeneration is a major research focus:
- Microglial Biology: Role of brain immune cells in disease
- Inflammatory Mediators: Cytokines and chemokines in neurodegeneration
- Autoimmune Components: Potential autoimmune contributions
- Therapeutic Implications: Anti-inflammatory treatment approaches
This research area has grown significantly with recognition of neuroinflammation as a disease contributor.
¶ Key Researchers and Faculty
UCLA hosts numerous investigators contributing to neurodegenerative disease research. The institution's faculty includes leading experts in Alzheimer's disease, Parkinson's disease, and related conditions.
Faculty members leading Alzheimer's disease research include investigators focused on:
- Clinical trials and therapeutic development
- Biomarker discovery and validation
- Genetics and molecular mechanisms
- Neuroimaging and functional studies
Movement disorder specialists at UCLA investigate:
- Deep brain stimulation and surgical treatments
- Neuroimaging of dopaminergic circuits
- Genetic forms of Parkinson's disease
- Non-motor symptoms and Lewy body dementia
The Easton Center provides comprehensive Alzheimer's disease care:
- Memory Disorders Clinic: Diagnostic evaluation and treatment
- Clinical Trials Unit: Access to cutting-edge therapies
- Caregiver Support Programs: Education and support for families
- Research Programs: Basic and translational investigations
The movement disorder program offers:
- Movement Disorder Clinic: Comprehensive Parkinson's disease care
- Deep Brain Stimulation Program: Surgical treatment evaluation and follow-up
- Physical Therapy: Exercise and rehabilitation programs
- Research Programs: Clinical and basic science investigations
UCLA has been a key contributor to ADNI, a landmark multi-center study establishing:
- Standardized neuroimaging protocols
- Biomarker validation frameworks
- Clinical trial design methodologies
- Open-access data resources
ADNI has transformed Alzheimer's disease clinical research globally.
UCLA's clinical trial capabilities include:
- Specialized trial units with dedicated staff
- Regulatory and compliance expertise
- Patient recruitment and retention programs
- Data management and analysis resources
¶ Biobank and Tissue Repository
The institution maintains repositories supporting research:
- Brain tissue bank for neuropathological studies
- CSF and blood sample collections
- DNA and induced cell lines
- Clinical database with longitudinal data
¶ Training and Education
UCLA provides training in neurodegenerative disease research:
- Residency and Fellowship Programs: Neurology residents and movement disorder fellows
- Graduate Training: PhD programs in neuroscience and related fields
- Postdoctoral Training: Research fellowships for early-career scientists
- Continuing Education: Courses and conferences for practicing clinicians
¶ Collaborations and Partnerships
UCLA participates in major national research consortia:
- Alzheimer's Disease Research Centers (ADRC): NIA-funded research network
- Parkinson's Foundation Centers of Excellence: Parkinson's care and research
- Clinical Trial Networks: Multi-site therapeutic trials
- Genetic Consortia: International genetic research collaborations
The institution maintains global research partnerships:
- European Research Consortia: Collaboration on large-scale studies
- Asian Partnerships: Studies in diverse populations
- Industry Collaborations: Pharmaceutical company partnerships
- Data Sharing Initiatives: Open-science collaborations
¶ Funding and Support
UCLA neurodegenerative disease research is supported by:
- National Institutes of Health (NIH): Primary federal funding source
- Alzheimer's Association: Research grants and fellowships
- Michael J. Fox Foundation: Parkinson's disease research
- Private Foundations: Disease-specific and general support
- Industry: Pharmaceutical company research agreements
UCLA continues to expand its neurodegenerative disease research program:
- Precision Medicine: Personalized approaches based on biomarkers and genetics
- Novel Therapeutics: Development of new disease-modifying treatments
- Early Detection: Population-based screening and early intervention
- Digital Health: Technology-enabled care and research